Medgenics Inc. Common Stock (MDGN) 6.99 $MDGN
Medgenics Reports Second Quarter Financial Results
GlobeNewswire - Wed Jul 16, 7:43AM CDT
Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three and six months ended June 30, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com.
Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award
GlobeNewswire - Wed Jun 18, 7:30PM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Garry Neil, M.D., Global Head, Research and Development, has been awarded the Food and Drug Administration's (FDA) Commissioner's Special Citation. The Citation was established as an expression of the Commissioner's personal appreciation, recognizing outstanding and significant service in the public interest related to activities of the FDA. Dr. Neil has been extensively involved with many aspects of FDA policy work, including his work with the Reagan-Udall Foundation for the FDA. The Foundation fosters collaborations between patient groups, industry, academia, and FDA scientists to design and conduct regulatory science research.
Medgenics to Present at Two Upcoming Healthcare Investor Conferences
GlobeNewswire - Mon Jun 16, 9:38AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that members of the senior management team will be participating in the following upcoming healthcare investor conferences.
Medgenics Announces First Patient Implanted in Phase 1/2 Clinical Trial of MDGN-201 (EPODURE)
GlobeNewswire - Thu Jun 05, 7:30AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that the first patient has been enrolled in its Phase 1/2 clinical trial of MDGN-201 (EPODURE).
Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Fri Mar 14, 6:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medgenics, Inc. ("Medgenics" or the "Company"
(NYSE: MDGN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Medgenics, Inc. Stock Incentive Plan.
Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump(TM), a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present a corporate overview at the 26 Annual ROTH Capital Growth Conference in Laguna Niguel on Tuesday, March 11, 2014 at 8:00am PDT.
Medgenics Reports 2013 Financial Results
GlobeNewswire - Thu Feb 20, 7:30AM CST
Medgenics, Inc. (NYSE MKT: MDGN) (LSE:MEDU) (LSE:MEDG), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced financial results for the fiscal year ended December 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC" of the Company's Annual Report on Form 10-K.
R&D Focus On Improving Existing Biopharmaceutical Molecules Drives the Market for Biobetters, According to a New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Fri Jan 24, 7:51AM CST
Follow us on LinkedIn - Biobetters or biosuperiors are novel molecules derived from successful, approved biologic products customized to enhance its overall efficacy. Biobetters are developed to offer superior characteristics over the originator biological molecule in terms of extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. As an improved version of the original drug, biobetters offer significant clinical and market advantages for biopharmaceutical companies thus encouraging R&D investments in this space. As innovative and affordable biologics capable of enhancing quality of care at lower costs, government support and funding is also on the rise. Given their ability to lower drug costs, expand access to drugs, infuse competition and accelerate biomedical innovation, biobetters are poised to witness strong growth in the coming years. A key challenge however is the lack of clear regulatory guidelines that make it difficult for manufacturers to receive marketing approval for biosuperiors.
Medgenics Issues Stock Options and Restricted Shares to Non-Executive Directors
Business Wire - Tue Jan 07, 11:59AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on January 2, 2014, the Company granted options to subscribe for 15,000 shares of the Company's common stock, par value US$0.0001 ("Common Shares" ("Options" and made a restricted share award of 7,000 Common Shares ("Restricted Shares" to each of Sol Barer, Isaac Blech, Alastair Clemow, Wilbur "Bill" Gantz, Joseph Grano, Jr., Joel Kanter, Stephen McMurray, and Andrew Pearlman, all non-executive directors of the Company, as part of their remuneration for the year.
Medgenics Announces Director Enters into Stock Trading Plan and Change of Adviser
Business Wire - Tue Dec 24, 6:30AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM), a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 23 December 2013, Dr. Andrew L. Pearlman, founder and a director, has established a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the AIM Rules for Companies as well as the Company's policies with respect to insider sales.
Medgenics Reports Open Market Purchase of Common Stock by Director
Business Wire - Wed Dec 18, 7:30AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company that he purchased 4,500 shares of common stock on the open market on December 16, 2013 at an average price of $5.7787 per share.
Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board
Business Wire - Mon Dec 16, 8:07AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 13, 2013, the Company was informed by Dr. Sol Barer, Medgenics' Chairman of the Board of Directors, that he purchased 20,000 shares of common stock on the open market on that day at an average price of $5.3711 per share.
SOL J. BARER of Medgenics, Inc. (MDGN)-NYSE M bought Shares of MDGN
M2 - Fri Sep 20, 10:10AM CDT
Reported by InsiderCow.com at 2013-09-19 15:23:19 ET
Medgenics Announces New Executive Leadership Team
Business Wire - Mon Sep 16, 6:30AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of a new executive leadership team with the goal of accelerating the development of the company's gene therapy platform and maximizing the value of the company's technology assets. The new executives are Michael Cola, President and Chief Executive Officer, John Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head of Research and Development. In addition, on September 13, 2013, Mr. Cola joined the Medgenics' Board of Directors.
Anemia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sblm26/anemia_pipeline) has announced the addition of the "Anemia - Pipeline Review, H2 2013" report to their offering. 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Scope - A snapshot of the global therapeutic scenario for Anemia. - A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Anemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Johnson & Johnson Hospira, Inc. Medgenics Inc. AMAG Pharmaceuticals, Inc. Medinox, Inc. Amgen Inc. Eli Lilly and Company GlaxoSmithKline plc Sangart, Inc. Rockwell Medical Technologies, Inc. Daiichi Sankyo Company, Ltd Lentigen Corporation Sangamo BioSciences, Inc. Gamida Cell Ltd. FibroGen, Inc. Reliance Life Sciences Pvt. Ltd. Novartis AG and many more... For more information visit http://www.researchandmarkets.com/research/sb...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
Business Wire - Tue Jul 09, 8:00AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.
Medgenics to Present at the 8th Annual JMP Securities Healthcare Conference
Business Wire - Mon Jul 08, 9:24AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will be presenting a corporate overview at the 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10th at 12:00 noon Eastern time at The St. Regis New York.
Medgenics Reports First Quarter 2013 Financial Results
Business Wire - Thu May 09, 8:15AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three months ended March 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC" of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com.
Medgenics Reports Second Quarter Financial Results
GlobeNewswire - Wed Jul 16, 7:43AM CDT
Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three and six months ended June 30, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com.
Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award
GlobeNewswire - Wed Jun 18, 7:30PM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Garry Neil, M.D., Global Head, Research and Development, has been awarded the Food and Drug Administration's (FDA) Commissioner's Special Citation. The Citation was established as an expression of the Commissioner's personal appreciation, recognizing outstanding and significant service in the public interest related to activities of the FDA. Dr. Neil has been extensively involved with many aspects of FDA policy work, including his work with the Reagan-Udall Foundation for the FDA. The Foundation fosters collaborations between patient groups, industry, academia, and FDA scientists to design and conduct regulatory science research.
Medgenics to Present at Two Upcoming Healthcare Investor Conferences
GlobeNewswire - Mon Jun 16, 9:38AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that members of the senior management team will be participating in the following upcoming healthcare investor conferences.
Medgenics Announces First Patient Implanted in Phase 1/2 Clinical Trial of MDGN-201 (EPODURE)
GlobeNewswire - Thu Jun 05, 7:30AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that the first patient has been enrolled in its Phase 1/2 clinical trial of MDGN-201 (EPODURE).
Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Fri Mar 14, 6:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medgenics, Inc. ("Medgenics" or the "Company"
(NYSE: MDGN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Medgenics, Inc. Stock Incentive Plan. Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump(TM), a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present a corporate overview at the 26 Annual ROTH Capital Growth Conference in Laguna Niguel on Tuesday, March 11, 2014 at 8:00am PDT.
Medgenics Reports 2013 Financial Results
GlobeNewswire - Thu Feb 20, 7:30AM CST
Medgenics, Inc. (NYSE MKT: MDGN) (LSE:MEDU) (LSE:MEDG), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced financial results for the fiscal year ended December 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC"
of the Company's Annual Report on Form 10-K. R&D Focus On Improving Existing Biopharmaceutical Molecules Drives the Market for Biobetters, According to a New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Fri Jan 24, 7:51AM CST
Follow us on LinkedIn - Biobetters or biosuperiors are novel molecules derived from successful, approved biologic products customized to enhance its overall efficacy. Biobetters are developed to offer superior characteristics over the originator biological molecule in terms of extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. As an improved version of the original drug, biobetters offer significant clinical and market advantages for biopharmaceutical companies thus encouraging R&D investments in this space. As innovative and affordable biologics capable of enhancing quality of care at lower costs, government support and funding is also on the rise. Given their ability to lower drug costs, expand access to drugs, infuse competition and accelerate biomedical innovation, biobetters are poised to witness strong growth in the coming years. A key challenge however is the lack of clear regulatory guidelines that make it difficult for manufacturers to receive marketing approval for biosuperiors.
Medgenics Issues Stock Options and Restricted Shares to Non-Executive Directors
Business Wire - Tue Jan 07, 11:59AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on January 2, 2014, the Company granted options to subscribe for 15,000 shares of the Company's common stock, par value US$0.0001 ("Common Shares"
("Options" and made a restricted share award of 7,000 Common Shares ("Restricted Shares" to each of Sol Barer, Isaac Blech, Alastair Clemow, Wilbur "Bill" Gantz, Joseph Grano, Jr., Joel Kanter, Stephen McMurray, and Andrew Pearlman, all non-executive directors of the Company, as part of their remuneration for the year. Medgenics Announces Director Enters into Stock Trading Plan and Change of Adviser
Business Wire - Tue Dec 24, 6:30AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM), a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 23 December 2013, Dr. Andrew L. Pearlman, founder and a director, has established a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the AIM Rules for Companies as well as the Company's policies with respect to insider sales.
Medgenics Reports Open Market Purchase of Common Stock by Director
Business Wire - Wed Dec 18, 7:30AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company that he purchased 4,500 shares of common stock on the open market on December 16, 2013 at an average price of $5.7787 per share.
Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board
Business Wire - Mon Dec 16, 8:07AM CST
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 13, 2013, the Company was informed by Dr. Sol Barer, Medgenics' Chairman of the Board of Directors, that he purchased 20,000 shares of common stock on the open market on that day at an average price of $5.3711 per share.
SOL J. BARER of Medgenics, Inc. (MDGN)-NYSE M bought Shares of MDGN
M2 - Fri Sep 20, 10:10AM CDT
Reported by InsiderCow.com at 2013-09-19 15:23:19 ET
Medgenics Announces New Executive Leadership Team
Business Wire - Mon Sep 16, 6:30AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of a new executive leadership team with the goal of accelerating the development of the company's gene therapy platform and maximizing the value of the company's technology assets. The new executives are Michael Cola, President and Chief Executive Officer, John Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head of Research and Development. In addition, on September 13, 2013, Mr. Cola joined the Medgenics' Board of Directors.
Anemia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sblm26/anemia_pipeline) has announced the addition of the "Anemia - Pipeline Review, H2 2013" report to their offering. 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Scope - A snapshot of the global therapeutic scenario for Anemia. - A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Anemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Johnson & Johnson Hospira, Inc. Medgenics Inc. AMAG Pharmaceuticals, Inc. Medinox, Inc. Amgen Inc. Eli Lilly and Company GlaxoSmithKline plc Sangart, Inc. Rockwell Medical Technologies, Inc. Daiichi Sankyo Company, Ltd Lentigen Corporation Sangamo BioSciences, Inc. Gamida Cell Ltd. FibroGen, Inc. Reliance Life Sciences Pvt. Ltd. Novartis AG and many more... For more information visit http://www.researchandmarkets.com/research/sb...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
Business Wire - Tue Jul 09, 8:00AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. Medgenics to Present at the 8th Annual JMP Securities Healthcare Conference
Business Wire - Mon Jul 08, 9:24AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will be presenting a corporate overview at the 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10th at 12:00 noon Eastern time at The St. Regis New York. Medgenics Reports First Quarter 2013 Financial Results
Business Wire - Thu May 09, 8:15AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three months ended March 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC" of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com. 
